The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction

Area of Science:

• Cardiovascular Pharmacology
• Myocardial Infarction Research
• Cardiac Remodeling Studies

Background:

• Long-acting calcium (Ca2+) channel blockers show promise for ischemic heart disease.
• The impact of these blockers on cardiac remodeling post-myocardial infarction (MI) remains incompletely understood.

Purpose of the Study:

• To investigate the effects of azelnidipine on left ventricular (LV) remodeling.
• To assess the impact of azelnidipine on systolic and diastolic dysfunction following MI in a rat model.

Main Methods:

• Myocardial infarction (MI) was induced in rats via ligation of the left anterior descending artery.
• Rats were divided into sham-operated, untreated MI, and azelnidipine-treated MI groups.
• Hemodynamic measurements and Doppler echocardiography were performed four weeks post-MI.

Main Results:

• Azelnidipine significantly prevented increases in LV weight and LV end-diastolic dimension compared to untreated MI rats.
• The drug improved ejection fraction (42% vs. 31%) and the E/A wave ratio (3.2 vs. 5.3) in treated rats.
• These improvements indicate enhanced systolic and diastolic function post-MI with azelnidipine treatment.

Conclusions:

• Azelnidipine effectively mitigates left ventricular remodeling after myocardial infarction.
• The administration of azelnidipine improves both systolic and diastolic cardiac function post-MI.
• Long-acting Ca2+ channel blockers represent a viable therapeutic strategy for managing post-MI cardiac dysfunction.